A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic IndividualsSandra Andorf, Kari C. Nadeau, Terri Brown Whitehorn et al.|EClinicalMedicine|2019Cited by 132
FDA-approved peanut allergy treatmentStephen A. Tilles, Daniel Petroni|Annals of Allergy Asthma & Immunology|2018Cited by 20
Current management and use of oral immunotherapy in the United States for patients with peanut allergyMichael S. Blaiss, Jay Liebermann, Stephen A. Tilles et al.|Allergy and Asthma Proceedings|2019Cited by 14
Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticariaTaha Al‐Shaikhly, William R. Henderson, James W. MacDonald et al.|Allergy|2020Cited by 7